Applied BioCode Corporation (TPE:6598)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
21.95
+0.05 (0.23%)
Apr 29, 2026, 1:30 PM CST
15.53%
Market Cap 2.25B
Revenue (ttm) 475.20M
Net Income (ttm) -201.20M
Shares Out 102.81M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 55,465
Average Volume 149,506
Open 21.90
Previous Close 21.90
Day's Range 21.50 - 21.95
52-Week Range 18.70 - 26.00
Beta 0.79
RSI 38.03
Earnings Date May 11, 2026

About Applied BioCode

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic ... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2016
Country Cayman Islands
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6598
Full Company Profile

Financial Performance

In 2025, Applied BioCode's revenue was 475.20 million, an increase of 38.52% compared to the previous year's 343.07 million. Losses were -201.20 million, -22.85% less than in 2024.

Financial Statements

News

There is no news available yet.